Anonymized samples were representative of the US blood donor population ( n = @ ) , healthy UK donors ( n = @ ) , patients with nonprion neurodegenerative diseases ( n = @ ) , patients in whom a prion disease diagnosis was likely ( n = @ ) , and patients with confirmed vCJD ( n = @ ) .